Our data confirm and expand on previous studies showing aberrant levels of progranulin in different cancer types, such as hematologic, digestive, and gynecologic cancers (Arechavaleta‐Velasco et al., 2017), as well as the pro‐mitogenic and pro‐survival roles of this protein in malignant cells (Arechavaleta‐Velasco et al., 2017). This evidence concerns the gene GRN and female reproductive organ cancer.